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ABSTRACT
Purpose: Glioblastoma multiforme (GBM) is the most aggressive brain tumor. The 
activity of vosaroxin, a first-in-class anticancer quinolone derivative that intercalates 
DNA and inhibits topoisomerase II, was investigated in GBM preclinical models as a 
single agent and combined with radiotherapy (RT).
Results: Vosaroxin showed antitumor activity in clonogenic survival assays, 
with IC50 of 10−100 nM, and demonstrated radiosensitization. Combined treatments 
exhibited significantly higher γH2Ax levels compared with controls. In xenograft models, 
vosaroxin reduced tumor growth and showed enhanced activity with RT; vosaroxin/RT 
combined was more effective than temozolomide/RT. Vosaroxin/RT triggered rapid 
and massive cell death with characteristics of necrosis. A minor proportion of treated 
cells underwent caspase-dependent apoptosis, in agreement with in vitro results. 
Vosaroxin/RT inhibited RT-induced autophagy, increasing necrosis. This was associated 
with increased recruitment of granulocytes, monocytes, and undifferentiated bone 
marrow–derived lymphoid cells. Pharmacokinetic analyses revealed adequate blood-
brain penetration of vosaroxin. Vosaroxin/RT increased disease-free survival (DFS) and 
overall survival (OS) significantly compared with RT, vosaroxin alone, temozolomide, 
and temozolomide/RT in the U251-luciferase orthotopic model.
Materials and Methods: Cellular, molecular, and antiproliferative effects of 
vosaroxin alone or combined with RT were evaluated in 13 GBM cell lines. Tumor 
growth delay was determined in U87MG, U251, and T98G xenograft mouse models.  
(DFS) and (OS) were assessed in orthotopic intrabrain models using luciferase-
transfected U251 cells by bioluminescence and magnetic resonance imaging. 
Conclusions: Vosaroxin demonstrated significant activity in vitro and in vivo in 
GBM models, and showed additive/synergistic activity when combined with RT in O6-
methylguanine methyltransferase-negative and -positive cell lines.
INTRODUCTION
Glioblastoma multiforme (GBM) is an aggressive 
brain tumor associated with invasive behavior, high 
rate of recurrence, and an average survival of less than 
15 months, irrespective of treatment [1–3]. Histologically, 
malignant gliomas are characterized by hypercellularity, 
nuclear pleomorphism, microvascular proliferation, 
pseudopalisading necrosis, reactive gliosis, microglial 
activation, disrupted vasculature, breakdown of the 
blood-brain barrier, and increases in hypoxia. The high 
malignancy of GBM is due to diffuse infiltration into the 
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brain, high resistance to apoptosis [4], robust angiogenesis 
[5], tumor cell heterogeneity [6], proliferation of cancer 
stem-like cells [7], and an inflammatory state that results 
in recruitment of circulating lymphocytes and monocytes. 
GBM tumors consist of a heterogeneous population of 
tumor cells and contain immune cells that, with tumor 
vasculature and the extracellular matrix, constitute the 
tumor microenvironment. Interactions among these 
different cell types and cytokines may promote tumor 
development and progression. Macrophages, specifically 
tumor-associated macrophages (TAMs), are the most 
common cell type among tumor-infiltrating immune 
cells [8, 9]. TAMs from human neoplasms express arginase 
1, interleukin (IL)-10, and transforming growth factor beta 
(TGF-β); these cytokines reduce the antitumor activity 
of T cells and natural killer cells, and modulate tumor 
proliferation, infiltration, and angiogenesis [10]. Previous 
studies of TAM populations in glioma tissues have 
shown that activated microglia/macrophages (especially 
M2) express high levels of CD68, CD163, CD204, and 
CD206 [11]. Cells expressing monocyte and M2 markers 
are found dispersed throughout the tumor parenchyma.
The recent progress in the treatment of malignant 
gliomas is attributable to the introduction of the 
alkylating agent temozolomide (TMZ [12]). However, 
resistance to TMZ resulting from O6-methylguanine 
methyltransferase (MGMT) expression remains a major 
issue. Elevation of MGMT expression has been associated 
with chemoresistance in a large fraction of GBM, while 
the resistance mechanisms of MGMT-negative tumors are 
not well understood [13]. Thus, there is a clear need for 
effective second-line agents in patients with GBM who 
developed drug resistance.
Type II topoisomerases are essential for the survival 
of eukaryotic cells [14]. These enzymes maintain DNA 
topology, disentangling DNA that becomes knotted, 
underwound, or overwound in the process of replication, and 
are required to maintain correct chromosome condensation, 
decondensation, and segregation. Topoisomerase II is 
a validated target of a number of therapeutics currently 
in use for the treatment of diverse cancers, including 
intercalative topoisomerase II-poisoning drugs such as the 
anthracyclines (doxorubicin, daunorubicin, and idarubicin), 
and the anthracenedione mitoxantrone [15–19]. Several 
topoisomerase II inhibitors are known to potentiate the 
effects of radiation on tumor cells, although the mechanisms 
of radiation sensitization remain an area of research [20–23]. 
Anthracyclines have effective and broad-spectrum 
antitumor activity but their clinical utility is often limited 
by systemic toxicity (eg, cardiotoxicity with doxorubicin) 
or drug resistance (frequently mediated by P-glycoprotein) 
[18, 19, 24, 25]. 
Vosaroxin is a naphthyridine analog (Figure 1), 
structurally related to quinolone antibacterials, that 
exerts its anticancer activity exclusively by DNA 
intercalation and inhibition of topoisomerase II, leading 
to site-selective DNA double-strand breaks and apoptosis 
[26–28]. Vosaroxin is not a substrate for P-glycoprotein 
drug pumps, and can induce apoptosis independent of 
p53, thereby avoiding two common mechanisms of drug 
resistance [29]. Vosaroxin has been shown to be active 
against various in vitro and in vivo tumor models including 
breast, bladder, pancreas, colon, ovarian, gastric, and lung 
cancer [29–35]. It has also shown synergistic activity 
with platinum agents, anthracyclines, antimetabolites, 
and targeted therapies in tumor models [36]. In a recently 
completed pivotal phase 3 study in relapsed or refractory 
acute myeloid leukemia (N = 711), no increase in organ-
specific toxicities (cardiac, renal, hepatic, or pulmonary) 
was observed with vosaroxin/cytarabine treatment in 
comparison with placebo/cytarabine treatment [37]. 
Nonclinical studies provide supportive evidence of an 
absence of toxic metabolite formation [31, 38]. 
Previously, vosaroxin has been shown to enhance 
radiosensitivity in several tumor cell types, including 
glioma cell lines [39]; the current study confirms and 
extends these findings. This study assessed the effect of 
vosaroxin on post-irradiation sensitivity in a series of 
13 glioma cell lines using clonogenic assay. Subsequent 
mechanistic and in vivo studies were performed with 
MGMT-negative/TMZ-sensitive (U87MG and U251) cells 
and MGMT-positive/TMZ-resistant (T98G) cells. In vivo 
radiosensitization was measured by subcutaneous tumor 
growth delay in U87MG and T98G models as well as in 
luciferase-transfected U251 cells injected orthotopically 
into the brains of female CD1 nu/nu nude mice.
RESULTS
Vosaroxin reduced cell viability and induced 
G2/M cell cycle arrest and apoptosis in glioma 
cell models
The effects of vosaroxin on cell viability were assessed 
in 13 human glioma cell lines and three patient-derived 
glioblastoma stem cell lines scored for MGMT, p53, and 
PTEN status (Table 1, Figure 2A). Vosaroxin demonstrated 
activity against all cell lines tested; 50% inhibitory 
concentration (IC50) values ranged between 12.8 nM and 
260.5 nM. Interestingly, vosaroxin was found to retain its 
cytotoxic activity when tested against both MGMT-negative/
TMZ-sensitive and MGMT-positive/TMZ-resistant cell lines 
(Figure 2B), in agreement with published data that suggested 
vosaroxin activity in multidrug-resistant (MDR) cell 
lines [30]. Similarly, no statistically significant differences 
were found by p53 or PTEN status (Figure 2B). Cell cycle 
analyses showed that vosaroxin induced G2/M cell cycle 
arrest (Figure 2C, left panels) in a dose- and time-dependent 
manner (data not shown). Single-agent vosaroxin showed 
low apoptotic-mediated cell death, but cell death increased 
when vosaroxin was combined with radiotherapy (RT) 
(Figure 2C, right panels) in U87MG, U251, and T98G cells. 
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Vosaroxin increased the effects of radiotherapy 
in glioma models in vitro
The effects of vosaroxin on the radiosensitivity of 
glioma cells were assessed in clonogenic assays. Because 
drug exposure times were longer during clonogenic survival 
studies with radiation, vosaroxin concentrations equal 
to the IC20 in growth inhibition assays were used; IC20 
values ranged between 10 nM and 100 nM. Treatment of 
glioma cells with vosaroxin alone resulted in a surviving 
fraction analyzed at 21 days of culture of 0.80 ± 0.064 in 
U251, 0.77 ± 0.18 in U87MG, 0.84 ± 0.036 in T98G, and 
0.87 ± 0.18 in A172 cells, which is an appropriate degree 
of cytotoxicity for evaluation of vosaroxin in combination 
with radiation. In the combination protocol, 48 hours after 
drug exposure, cell cultures were irradiated at 2, 4, and 6 Gy 
and colony-forming efficiency was determined 21 days later 
in U251, U87MG, T98G, and A172 cells (Figure 3). This 
treatment resulted in a dose enhancement factor of 1.33 in 
U251, 1.55 in U87MG, 1.40 in T98G, and 1.24 in A172 
cells, calculated at a surviving fraction of 0.10. Our results 
are in agreement with those of Gordon et al. 2012 [39].
Assessments of the mechanism of 
radiosensitization
The mechanisms underlying neoplastic cell killing 
by ionizing radiation are largely unknown. We analyzed 
the modality of radiosensitization in U87MG, U251, 
and T98G cells as models of high, moderate, and low 
radiosensitivity, respectively. Increased autophagic 
responses have been associated with increased 
radioresistance [40, 41]; therefore, we analyzed cells 
treated with RT (4 Gy), vosaroxin (at concentrations 
corresponding to the IC20 value for each cell line), and 
the combination for the appearance of autophagy by 
evaluating the development of acidic vesicular organelles 
(AVOs) at 24 hours. RT increased the percentage of 
AVO-stained cells. As shown in Figure 4A, the levels of 
RT-induced AVO staining were further increased by the 
pan-caspase inhibitor z-Val-Ala-Asp(Ome)-fluoromethyl 
ketone (10 μM) and reduced by the autophagy inhibitor 
3-methyladenine (5 μM). The addition of vosaroxin 
reduced AVO staining (Figure 4B), suggesting that 
vosaroxin inhibited RT-induced autophagy. Additionally, 
RT-induced levels of beclin-1, a marker for autophagy, 
were significantly reduced after vosaroxin treatment 
(Figure 4C), in agreement with AVO staining. In contrast, 
caspase-3 activity was increased with the addition 
of vosaroxin (Figure 4D), indicating potentiation of 
RT-induced apoptosis. 
Since vosaroxin and RT can cause DNA double-
strand breaks, levels of γH2Ax in treated cells were 
assessed by immunohistochemistry, Western blot, and 
enzyme-linked immunosorbent assay (ELISA). Increased 
γH2Ax expression following treatment with vosaroxin, 
RT, and the combination was observed in T98G cultures 
by immunohistochemistry (Figure 4E). The percentage 
of mitotic cells observed in these cultures was higher 
in control versus vosaroxin-treated cell cultures (Figure 
4F); however, an increased presence of H2Ax-positive 
aberrant mitotic cells was observed after treatment 
with vosaroxin and/or RT (Figure 4E, black arrows). 
Expression of γH2Ax, as detected by Western blot and 
ELISA, increased after combination treatment (vosaroxin 
plus RT) compared with vosaroxin or RT alone in all 
cell lines tested (Figure 4G). In the absence of vosaroxin 
pretreatment, γH2Ax expression reached maximum 
levels at 16 hours after irradiation (4 Gy) and returned to 
baseline values after 24 hours (Figure 4H). In the presence 
of vosaroxin, the expression of γH2Ax was higher at 
each time point relative to non-pretreated cells; γH2Ax 
expression reached maximal levels at 24 hours and values 
did not return to baseline by 48 hours (Figure 4H). The 
increased γH2Ax levels observed with vosaroxin at later 
time points indicated a prolonged DNA damage response, 
possibly suggesting that double-stranded breaks were not 
sufficiently repaired in treated conditions.
Figure 1: Chemical structure of vosaroxin.
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Vosaroxin increased the effects of radiotherapy 
in xenograft models of GBM
The effects of vosaroxin alone and in combination 
with RT were evaluated in vivo in U251, U87MG, and 
T98G GBM xenograft models. Effects on TTP and tumor 
weight after 35 days were compared to treatment with TMZ, 
as a single agent and in combination with RT (Figure 5).
In U87MG, U251, and T98G xenografts, final tumor 
weight was reduced by 44%, 42%, and 60%, respectively, 
with vosaroxin treatment compared with vehicle controls 
(Figure 5A, 5C, 5E). The addition of vosaroxin increased 
the antitumor effects of RT; combination treatment 
reduced final tumor weight by 87%, 79%, and 57% 
(compared with vehicle) whereas RT alone reduced 
final tumor weight by 30%, 23%, and 33% in U87MG 
(combination index [CI] = 0.52), U251 (CI = 0.48), and 
T98G (CI = 0.78) xenografts, respectively. The CI values 
suggested synergy between vosaroxin and RT in these 
tumor models. Temozolomide demonstrated efficacy 
similar to single-agent vosaroxin in U87MG and U251 
cells, with final tumor weight reductions of 53% and 54% 
when compared with controls, while a smaller effect (25% 
reduction versus control) was observed in T98G cells. 
Temozolomide also increased RT sensitivity, with tumor 
weight reductions (compared with vehicle control) of 
83% (CI = 0.85), 71% (CI = 0.74), and 57% (CI = 0.89), 
respectively. CI values for temozolomide were also in the 
range of synergism, but were higher than those observed 
with RT combined with vosaroxin. 
Similar evidence of synergy was apparent when 
we assessed TTP (Figure 5B, 5D, 5F) in U87MG, U251, 
and T98G xenograft models. Hazard ratios comparing 
TTP with various treatments in U87MG, U251, and 
T98G xenograft models are shown in Table 2 (additional 
comparisons in Supplementary Table 1). In Kaplan-Meier 
analyses, probability of tumor progression in U87MG 
xenografts was reduced with RT or single-agent vosaroxin, 
compared with untreated animals (Figure 5B, Table 2). 
Vosaroxin in combination with RT significantly reduced 
the probability of tumor progression compared with RT or 
vosaroxin alone. In this radio- and chemosensitive model, 
temozolomide reduced tumor progression in comparison 
with untreated animals and was a good radiosensitizing 
agent in agreement with previously reported data, with no 
statistically significant differences in the radiosensitizing 
effects of vosaroxin versus temozolomide. Similar results 
were obtained for U251 xenografts (Figure 5D, Table 2). 
In this model, vosaroxin appeared to be a more effective 
radiosensitizer than temozolomide, although the difference 
was not statistically significant, likely due to small 
sample size. A more marked difference in the effects of 
vosaroxin and temozolomide on the probability of tumor 
progression was observed in the radio- and chemoresistant 
T98G xenograft model (Figure 5F, Table 2). In this model, 
vosaroxin demonstrated higher antitumor activity than 
temozolomide, in terms of tumor progression, both as 
single-agent treatment (P = 0.495) and in combination 
with RT (P < 0.0001). 
Histopathological appearance of experimental 
gliomas
U87MG, U251, and T98G xenograft tumors 
grew rapidly with pleomorphism and high density 
of microvessels, which are typically seen in human 
Table 1: IC50 values for vosaroxin in glioma cell lines
Cell Line IC50 ± SD (nM) MGMT Status P53 status PTEN status
LN229 12.8 ± 2.3 Methylated Deficient Mutated
U251 18.6 ± 2.4 Methylated Unfunctional Mutated
SNB19 35.5 ± 7.0 Methylated Unfunctional Mutated
SF268 50.3 ± 12.0 Methylated Unfunctional PTEN-harboring
T98G 64.5 ± 11.0 Unmethylated Unfunctional PTEN-harboring
U138 65.8 ± 14.6 Unmethylated Deficient PTEN-harboring
U373 78.4 ± 9.7 Methylated Unfunctional Mutated
U118 88.5 ± 16.7 Unmethylated Deficient Mutated
LN18 90.0 ± 12.5 Unmethylated Active (WT) PTEN-harboring
A172 125.4 ± 89.4 Methylated Active (WT) Mutated
U87MG 140.9 ± 84.7 Methylated Active (WT) PTEN-deficient
SW1783 260.5 ± 9.8 Unmethylated Unfunctional Mutated
D54 190.0 ± 25.4 Unmethylated Active (WT) Wild type
BT12M 44.3 ± 5.5 Unmethylated Active (WT) Wild type
CSCs-5 85.4 ± 7.8 Methylated Active (WT) PTEN-deficient
CSCs-7 125.0 ± 15.4 Unmethylated Unfunctional Wild type
IC50: 50% inhibitory concentration; MGMT: O6-methylguanine methyltransferase; PTEN: phosphatase and tensin homolog 
(gene); SD: standard deviation; WT: wild type.
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Figure 2: Effects of vosaroxin on glioma cell lines. (A) Growth inhibition curves for U251, T98G, A172, and U87MG glioma cell 
lines treated with vosaroxin, generated with Grafit software. (B) No statistically significant differences were found in the IC50 of vosaroxin 
in glioma cell lines by MGMT, p53, or PTEN status. (C) Cell cycle analysis of vosaroxin-induced G2/M cell cycle arrest (left panels), and 
combination effects of vosaroxin (20 nM) and radiotherapy on cell cycle arrest and apoptosis in U87MG, U251 and T98G cells (bar graphs 
in right panels).
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GBM. Histopathological analysis revealed presence 
of glial neoplasia consisting of tightly packed sheets 
of heterogeneous tumor cell population with round to 
polygonal cell morphology (Supplementary Figure 1A), or 
spindle-shaped cell morphology with abundant, intensely 
eosinophilic cytoplasm and hyperchromatic nuclei and 
nucleoli (Supplementary Figure 1B). Bizarre gigantic cells 
with hyperchromatic round nuclei and elevated nuclear 
pleomorphism were also present. Tumor cells in rapid 
growth were dispersed on a fibrillar collagen background 
(Supplementary Figure 1C) that enveloped abundant 
vasculature (Supplementary Figure 1D). A narrow band 
of leukocyte infiltrate, consisting of granulocytes, B 
lymphocytes, and monocyte/macrophages, surrounded the 
tumors (Supplementary Figure 1E) and are indispensable 
components of the neoplastic microenvironment that can 
modulate the biological behavior of this malignancy. 
Tissues were characterized by pseudopalisading necrosis 
(present in central areas of tumors and in the largest 
tumors as uncontrolled tumor growth and subsequent 
hypoxia) in a garland-like arrangement of hypercellular 
tumor nuclei lining up around tumor necrosis-containing 
pyknotic nuclei (Supplementary Figure 1F). Additional 
features included thrombotic vessels and hemorrhage 
(Supplementary Figure 1G). 
Histopathological and immunohistochemical 
changes with RT and/or vosaroxin treatment
Leukocyte infiltration was shown to be a common 
event in GBM growth, both in human patients and in 
experimental preclinical animal models (reviewed in 
Bienkowski and Preusser 2015 [42]). U251 xenografts 
demonstrated an infiltration of small rounded and 
mononucleated cells that were morphologically similar to 
leukocytes (Figure 6A). A smaller amount of granulocyte 
infiltration by multinucleated cells was also observed. 
Leukocytes were concentrated along the surface of the 
tumors but were also dispersed among the individual 
tumor cells. RT increased the accumulation/recruitment 
of leukocytes compared with untreated tumors and dense 
leukocyte infiltrates extended along the edges of growth 
(Figure 6B). A further increase in leukocyte recruitment 
was observed in tissues harvested from mice treated with 
vosaroxin (Figure 6C). When vosaroxin and RT were 
combined, the presence of leukocytes appeared to be 
Figure 3: Radiosensitizing effects of vosaroxin on glioma cell lines. Clonogenic curves for (A) U251, (B) U87MG, (C) T98G, 
and (D) A172 cells treated with vosaroxin (solid line) and control (no vosaroxin; dashed line).
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Figure 4: Molecular and cytologic analyses of the mechanisms of radiosensitization by vosaroxin. To define the molecular 
mechanisms involved in radiosensitization by vosaroxin we treated cells with radiotherapy (RT; at 2, 4, and 6 Gy) and vosaroxin at 
concentrations equal to IC20 values (15 nM for U251, 65 nM for U87MG, and 45 nM for T98G cells). (A) Percentage of acidic vesicular 
organelle (AVO)-stained glioma cells 24 hours after RT treatment (4 Gy). Percentage of AVO-stained cells was increased by the pan-caspase 
inhibitor z-Val-Ala-Asp(Ome)-fluoromethyl ketone (VAAFK, 10 μM) and was reduced by the autophagy inhibitor 3-methyladenine (3MA, 
5 μM). (B) Percentage of AVO-stained cells after treatment with RT, vosaroxin (VSR), or the combination. CTRL: control. (C) Modulation 
of expression of an autophagy marker, beclin-1, by RT, vosaroxin, and combination vosaroxin plus RT by Western blot and ELISA. (D) 
Caspase-3 activity in treated and control cell cultures. (E) Immunocytochemical appearance of γH2Ax expression in T98G cultures after 
RT, vosaroxin, and combination RT plus vosaroxin for 24 hours. (F) Percentage of mitosis in U87MG, U251, and T98G cultures after 
single-agent or combination treatment. (G) γH2Ax expression in U87MG, U251, and T98G cells at 24 hours of treatment. (H) Expression 
of γH2Ax by ELISA and Western blotting measured in U87MG cells at 1, 4, 8, 16, 24, and 48 hours after 4 Gy irradiation with or without 
vosaroxin pre-treatment.
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associated with increased local proliferation of hematopoietic 
cells in dense clusters, suggesting a possible recruitment 
of circulating myeloid cells (Figure 6D). Staining with 
leukocyte-specific anti-CD68 antibodies suggested 
infiltration primarily by mononucleated monocytes, B 
lymphocytes, and natural killer cells (Figure 6E–6H).
Accumulating evidence supports the notion that RT 
triggers strong proimmunogenic effects with increased 
expression of both proinflammatory and anti-inflammatory/
immune-tolerant cytokines produced by both tumor 
cells and murine stromal cells, including IL-1β, tumor 
necrosis factor (TNF)-α, TGF-β, IL-6 , IL-8, and IL-10 
Figure 5: Radiosensitizing effects of vosaroxin on tumor weight and time to progression in xenograft models. To assess 
the effect on tumors in an in vivo model, 1 × 106 cells of U251, U87MG, and T98G GBM cells were subcutaneously injected in female 
cd1 nu/nu mice. When tumors reached a volume of 80 mm3 (about 10 days after cell injection), animals were randomized to receive 
radiotherapy (RT) alone (1 single dose of 4 Gy), vosaroxin (VSR; 10 mg/kg q 5 d for 5 wk), or vosaroxin (10 mg/kg q 5 d for 5 wk) plus 
RT (1 single dose of 4 Gy administered after 3 days of vosaroxin treatment). These treatments were compared with standard therapies 
consisting of temozolomide (TMZ; 16 mg/kg ´ 5 consecutive days) and temozolomide plus RT. Changes in tumor volumes were measured 
over time. After 35 days, animals were sacrificed and tumors harvested and weighed. Final tumor weights (at day 35) and Kaplan-Meier 
analysis of time to progression are shown for: (A, B) U87MG; (C, D) U251; and (E, F) T98G xenograft models. CTRL: control.
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(reviewed in Leroi et al. 2016 [43]). An important role 
of TNF-α has been its association with chemosensitivity 
in GBM. It has been shown that increased expression 
and secretion of biologically active TNF-α reduces 
P-glycoprotein expression and is associated with increased 
cytotoxicity of the MDR-relevant chemotherapeutic agents 
[44], which could result in a higher sensitivity to TMZ 
chemotherapy. 
CD68 expression (a monocyte marker) was 
detected in treated T98G xenografts (Figure 6E–6H), 
and levels of pro- and anti-inflammatory cytokines 
were quantified from tissue extracts (Table 3). Cytokine 
levels were consistent with the morphological data 
and were suggestive of an active, acute inflammatory 
response following vosaroxin treatment. We observed 
that leukocyte recruitment and cytokine production were 
sustained after RT administration. Vosaroxin increased the 
production of proinflammatory (IL-1β, IL-6, and TNF-α) 
or angiogenetic (IL-8) cytokines, while the expression of 
stromal cell-derived factor (SDF)-1α, TGF-β1, and IL-10 
was reduced with vosaroxin treatment (Table 3). The 
increased expression of SDF-1α and TGF-β1 agrees with 
previously reported data that suggested acute inflammation 
may switch from acute to chronic inflammation in 
response to increased tumor cell death after treatment. 
This switch may be associated with an adverse tumor 
microenvironment associated with a poor outcome 
[45, 46]. SDF-1α and TGF-β1 are involved in promoting 
Figure 6: Leukocyte infiltration with vosaroxin and/or RT. Panels (A–D) show the histologic appearance of U251 xenografts 
at low (50´; upper row) and high (400´; lower row) magnification in (A) untreated U251 xenografts, (B) after radiotherapy (RT), (C) after 
treatment with vosaroxin, and (D) after vosaroxin was added to RT. Panels (E–H) display immunostaining for CD68 expression at low 
magnification (50×) for untreated T98G tumors (E), and T98G tumors treated with RT (F), vosaroxin (G), and vosaroxin and RT (H).
Table 2: Probability of tumor progression in xenograft models
Treatments Compared
U87MG U251 T98G
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
VSR vs TMZ 0.6 (0.2–1.5) 0.20 (NS) 0.6 (0.3–1.6) 0.23 (NS) 0.5 (0.2–1.3) 0.0495
RT vs VSR + RT 6.2 (1.9–20.6) < 0.0001 4.6 (1.5–14.8) < 0.0001 4.6 (1.5–14.3) < 0.0001
VSR vs VSR + RT 4.3 (1.2–15.6) < 0.001 4.0 (1.3–12.1) < 0.0001 4.7 (1.5–14.6) < 0.0001
VSR vs TMZ + RT 0.8 (0.3–2.0) 0.64 (NS) 4.2 (1.4–12.5) 0.0002 1.0 (0.4–2.4) 0.97 (NS)
VSR + RT vs TMZ + RT 0.2 (0.1–0.8) 0.0054 0.5 (0.2–1.3) 0.11 (NS) 0.21 (0.1–0.7) < 0.0001
CI: confidence interval; HR: hazard ratio for tumor progression; NS: not significant; RT: radiotherapy; TMZ: temozolomide; 
VSR: vosaroxin.
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tumor growth, whereas proinflammatory cytokines, such 
as Il-1β and TNF-α are mainly produced by classically 
activated (M1 polarized) tumor-associated microglia/
macrophages. The latter display antitumor activity. Thus, 
the observed increase in proinflammatory cytokines may 
be an indication of an additional protective mechanism of 
vosaroxin (for review see Dello Russo C et al. 2016) [47].
A previous study has suggested that CD38 and 
iNOS expression were associated primarily with M1 
macrophages in the murine system, whereas Egr2, 
c-myc-1, and arginase-1 expression were exclusive 
associated with M2 macrophages [48]. To further 
define the role of TAMs in the antitumor effects of RT 
and vosaroxin, iNOS and arginase-1 expression were 
assessed in tissue extracts from U87MG, U251, and T98G 
xenografts following study treatments. The results showed 
low expression of M1-associated iNOS after RT, but with 
high expression levels of arginase-1 when compared with 
controls (Supplementary Figure 2). In contrast, vosaroxin 
treatment was associated with high expression of iNOS 
and low expression of arginase-1. When combined, the 
arginase-1 and iNOS expression levels were similar to 
those of vosaroxin alone.
Necrosis in the xenograft tumor models was 
increased with treatment, representing 30%–40% of 
the tumor mass in the vosaroxin-treated animals and up 
Table 3: Cytokine expression in glioma xenograft models after treatment with radiation and/or 
vosaroxin
Cytokine Treatment U87MG U251 T98G
IL-1βa Control 60 ± 15 35 ± 7 21 ± 4
RT 120 ± 40 77 ± 8 35 ± 6
Vosaroxin 85 ± 10 44 ± 5 27 ± 4
Vosaroxin + RT 425 ± 15 72 ± 13 124 ± 35
TNF-αb Control 25 ± 12 5 ± 1 10 ± 1
RT 43 ± 13 13 ± 3 18 ± 2
Vosaroxin 17 ± 3 7 ± 1 3 ± 1
Vosaroxin + RT 80 ± 12 44 ± 8 80 ± 5
IL-6c Control 51 ± 7 120 ± 21 177 ± 15
RT 60 ± 14 58 ± 12 72 ± 23
Vosaroxin 78 ± 13 33 ± 8 30 ± 3
Vosaroxin + RT 180 ± 44 684 ± 28 360 ± 40
IL-8d Control 512 ± 28 213 ± 13 344 ± 44
RT 750 ± 60 330 ± 44 535 ± 37
Vosaroxin 715 ± 37 275 ± 35 440 ± 30
Vosaroxin + RT 1200 ± 230 750 ± 48 917 ± 48
SDF-1αe Control 11 ± 5 24 ± 6 18 ± 5
RT 77 ± 12 43 ± 8 38 ± 6
Vosaroxin 18 ± 3 32 ± 3 12 ± 4
Vosaroxin + RT 57 ± 5 36 ± 5 22 ± 6
TGF-β1f Control 43 ± 13 25 ± 5 35 ± 8
RT 84 ±15 88 ± 12 75 ± 8
Vosaroxin 47 ± 8 35 ± 6 27 ± 3
Vosaroxin + RT 67 ± 12 62 ± 8 55 ± 7
IL-10g Control 2.5 ± 0.3 < 1.0 < 1.0
RT 34.2 ± 0.8 18.3 ± 0.5 35.2 ± 3.5
Vosaroxin 6.2 ± 0.5 5.2 ± 0.6 < 1.0
Vosaroxin + RT 12.6 ± 0.2 6.4 ± 0.5 5.2 ± 0.4
aMouse IL-1β (pg/mg tissue). No human IL-1β was present.
bHuman TNF-α (pg/mg tissue). 5–40 pg/mg tissue was also of mouse origin and was increased with treatments (data not shown).
cHuman IL-6 (pg/mg tissue). Lower levels of IL-6 were observed when specific murine ELISA was used (about 10% of human 
IL-6).
dHuman and mouse IL-8 (pg/mg tissue).
eMouse SDF-1α. Contribution of human SDF-1α 5%–15%.
fHuman TFG-β1.
gMouse IL-10.
IL: interleukin; RT: radiotherapy; SDF: stromal cell-derived factor; TGF: transforming growth factor; TNF: tumor necrosis factor.
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to 70% in animals with U251 xenografts treated with 
vosaroxin and RT (Figure 7A–7D), and was increased 
in peripheral tumor zones. Quantification of necrosis 
is shown in Figure 7E. The increase in tumor necrosis 
is consistent with the observed elevation in leukocyte 
infiltration. 
Tumor vasculature was also impacted by treatment. 
Tumors from control animals had more numerous and 
larger superficial blood vessels than treated animals. 
The impacted vessels occurred near the periphery of the 
tumor (near the tumor–host interface) and may display 
characteristics of tumor angiogenesis and angiogenesis 
associated with the wound response. In addition to 
considerable necrosis areas, hemorrhage and edema in the 
tissue surrounding the tumor growth region were observed 
in the normal parenchyma encircling the tumor; this 
appearance was increased after treatment with vosaroxin 
and vosaroxin plus RT. Tumors with necrotic regions have 
an inadequate blood supply and are expected to differ 
from well-vascularized tumors in response to treatment. 
The percentage of necrotic areas was significantly 
increased after combined treatment with vosaroxin and RT, 
suggesting a close correlation between study treatment and 
necrosis in all three models (Figure 7E). The quantification 
of hemoglobin in tumors (Figure 7F) revealed that 
treatments were able to reduce the influx of blood in tumor 
tissues in all 3 xenografts used for this analysis. 
Increased fibrosis and reduced angiogenesis are 
related to reduced Ki67 expression. Ki67 expression 
was evaluated by immunohistochemistry in T98G 
xenografts treated with RT, vosaroxin, or the combination 
(Figure 8A). The percentage of Ki67-positive cells was 
markedly reduced with treatment (Figure 8C). Consistent 
with in vitro data, we also observed a reduction of LTG5, 
an autophagic molecular marker, with combination 
treatment relative to RT alone (Figure 8B and 8D). Massive 
apoptosis was associated with cleavage of caspase-3 and 
caspase-8 (Figure 8E, 8F) as well as increased FASL 
expression (Figure 8G) in T98G xenografts. 
Distribution of vosaroxin to brain in mice
After administration of [14C]-vosaroxin (20 mg/kg) 
to human nasopharyngeal tumor-bearing mice, 
radioactivity distributed rapidly, with only 2.6% to 1% 
remaining in the blood compartment at 8 hours postdose 
(Table 4). Maximum concentration in the cerebrum was 
0.744 µgeq/g or 1.85 µMeq/g and in the cerebellum 
was 0.811 µgeq/g or 2.02 µMeq/g. Although brain 
tissues (cerebrum and cerebellum) showed tissue:plasma 
ratios ≤ 1.5, radioactivity in the brain achieved 
concentrations associated with anticancer activity in 
vitro [32, 39]. These data suggested that active levels of 
vosaroxin may be achieved in the brain clinically where 
dose levels similar to or higher than 60 mg/m2 have been 
investigated [37, 49, 50]. 
Orthotopic GBM model
The efficacy of vosaroxin was investigated in an 
orthotopic mouse model using luciferase-transfected U251 
cells. We deliberately inoculated a small number of cells 
(3 × 103) to simulate treatment postsurgery, where a low 
number of tumor cells remaining in the operatory bed were 
able to regrow into a recurrent lesion. Treatments were 
started 5 days after cell injection when no luciferase activity 
was detectable intracranially; the animals were treated for 
35 days and followed for a maximum of 185 days. 
Representative intrabrain lesions assessed by 
bioluminescence intensity and MRI are shown in Figure 9A 
and 9B. Control mice developed a bioluminescent lesion 
between 12 and 30 days with a mean of 18.1 ± 1.7 
(standard error [SE]) days. Supplementary Figure 3A 
and 3B show recurrence probability over time (equivalent 
of disease-free survival [DFS]) and Figure 9C and 9D 
show overall survival (OS). Hazard ratios comparing 
DFS and OS with various treatments in U251 orthotopic 
models are shown in Table 5 (additional comparisons 
in Supplementary Table 2). RT increased DFS, slowing 
mean recurrence to 43.5 ± 2.9 days (P < 0.0001). Mean 
recurrence was also significantly slowed with vosaroxin 
(70.5 ± 7.3 days; P < 0.0001) and temozolomide 
(68.3 ± 5.4 days; P < 0.0001) treatment. Combination 
treatment further slowed mean time of recurrence: mean 
DFS with temozolomide plus RT was 82.5 ± 5.3 days 
(P < 0.0001 compared with temozolomide alone and 
P = 0.0023 compared with RT alone); mean DFS with 
vosaroxin plus RT was 96.5 ± 6.3 days (P = 0.0244 versus 
vosaroxin alone and P = 0.0088 versus temozolomide 
plus RT). These data indicated that vosaroxin produced 
greater increases in DFS than temozolomide, alone and in 
combination with RT, in MGMT-negative glioblastomas. 
Similar results were observed in analyses of OS in mice 
treated with vosaroxin or temozolomide alone or in 
combination with RT.
DISCUSSION
The potential of topoisomerase II as a target for 
radiosensitization has been previously suggested in 
studies with other agents in experimental tumor models 
[20–23, 39, 51]. Radiation causes cells to arrest in G2/M 
phase, which is when topoisomerase II typically functions 
in replication and repair. Topoisomerase II inhibitors 
can cause G2 arrest, which places cells in a relatively 
radiosensitive phase of the cell cycle [39, 51, 52]. 
However, the clinical utility of topoisomerase II inhibitors 
is limited by systemic toxicity and drug resistance that is 
frequently mediated by P-glycoprotein. [18, 19, 24, 25]. 
Vosaroxin is a novel topoisomerase II inhibitor that 
is not a substrate for P-glycoprotein drug pumps, and can 
induce apoptosis independent of p53, thereby avoiding 
two common mechanisms of drug resistance [29]. It has 
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been shown to be active against various preclinical models 
and demonstrated synergistic activity in combination with 
other antineoplastic agents [29–35]. 
In this study, we evaluated vosaroxin in preclinical 
models of GBM with and without RT and showed that 
vosaroxin’s antitumor effects in GBM models were not 
impacted by MGMT, p53, or PTEN expression. 
The data presented here indicate that there was 
no significant initial increase in DNA damage based on 
γH2Ax expression at early time points after radiation, 
suggesting no increase in the number of DNA double-
strand breaks. However, at 24 hours after radiation, there 
were increased γH2Ax foci, suggesting that vosaroxin 
inhibits the repair of radiation-induced DNA damage in 
Figure 7: Necrosis in U251 xenograft tumors treated with vosaroxin and/or RT. (A–D) staining for necrosis in U251 xenografts 
at low (50×; upper row) and high (400×; lower row) magnification in untreated tumors (A) and tumors treated with RT (B), vosaroxin (C), 
and RT plus vosaroxin (D). (E) Graphical analysis on percentage of necrotic cells in U87MG, U251, and T98G xenografts after various 
treatments. (F) Quantification of the amount of hemoglobin (as an indirect measure of vasculature) present in tissue extracts from U87MG, 
U251, and T98G xenografts after various treatments. CTRL: control; RT: radiotherapy; VSR: vosaroxin.
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Figure 8: Expression of proliferation, autophagic, and apoptotic markers. Immunohistochemical staining for expression of (A) 
Ki67 and (B) LTG5 in untreated and treated T98G xenografts. Quantification of Ki67 expression (C) and LTG5 expression (D) in U87MG, 
U251, and T98G xenografts. Immunohistochemical staining for caspase-3 expression (E) and Western blot analyses of caspase-3 and 
caspase-8 levels in tissue extracts (F) for untreated and treated T98G xenografts. (G) Immunohistochemical staining for FasL expression in 
the T98G xenograft model. CTRL: control; RT: radiotherapy; VSR: vosaroxin.
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GBM cells. A previous study evaluating the topoisomerase 
II inhibitors amrubicin and amrubicinol in lung 
adenocarcinoma showed enhancement of radiosensitivity 
similar to the results reported here [20–23, 39]. Similar 
to our findings, this study showed increased necrosis 
when cells were irradiated and treated with topoisomerase 
inhibitors. In our study, we also demonstrated an increased 
proportion of necrotic cells in vivo after radiation and 
vosaroxin treatment, with subadditive increases in percent 
necrosis in the combination-treated cells. Vosaroxin was 
able to cross the blood-brain barrier and infiltrate brain 
tumors at concentrations compatible with IC50 values 
identified in this study.
We hypothesize that vosaroxin may induce 
radiosensitization through an enhancement of apoptosis 
and reduced autophagy. It has been recently demonstrated 
that topoisomerase IIα is highly expressed in glioblastoma 
stem cell lines and that inhibition of topoisomerase IIα 
Table 4: Distribution of [14C]-vosaroxin to brain in human nasopharyngeal tumor-bearing mice
Concentration µg equivalent of vosaroxin/mL or gram (tissue/plasma ratio)
5 min 30 min 1 h 3 h 8 h 24 h
Plasma 3.091 ± 0.104 (1.0) 1.885 ± 0.097 (1.0) 1.061 ± 0.071 (1.0) 0.544 ± 0.046 (1.0) 0.189 ± 0.006 (1.0) < LOD
Cerebrum 0.573 ± 0.097 (0.2) 0.744 ± 0.056 (0.4) 0.559 ± 0.071 (0.5) 0.307 ± 0.007 (0.6) 0.275 ± 0.053 (1.5) < LOD
Cerebellum 0.773 ± 0.081 (0.3) 0.811 ± 0.071 (0.4) 0.709 ± 0.055 (0.7) 0.607 ± 0.045 (1.1) 0.290 ± 0.042 (1.5) < LOD
LOD: limit of detection.
Figure 9: In vivo experiments: orthotopic intrabrain model. (A) Representative images of relative bioluminescence intensity 
(BLI) in brain lesion recurrence after orthotopic cell injections. (B) Representative MRI images of brain lesion recurrence. (C) Comparison 
of the effects of single treatments versus control (CTRL) on overall survival. (D) Comparison of the radiosensitizing effects of temozolomide 
(TMZ) and vosaroxin (VSR) on overall survival. Note: images in 9A and 9B are not representation of dose- or time-response data.
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with siRNA decreases cell proliferation and induces 
apoptosis in germline stem cells (GSCs) [53]. This effect 
may amplify the antitumor effects of vosaroxin through 
reduction of tumor growth and tumor recurrence by 
GSCs. The effect on GSCs may possibly be increased by 
reducing the expression of pro-stem cell regrowth factors 
(inflammatory cytokines TGF-β1, IL-10, and SDF-1α).
As this is the first study to evaluate the radiation-
sensitizing properties of vosaroxin, we further 
explored possible mechanisms of these properties. 
Increasing evidence suggests that an inflammatory, 
immunosuppressive tumor microenvironment may 
promote invasion by GBM cells [54, 55] through the 
activation of pathways that recruit myeloid precursors. 
One interesting possible mechanism involved in the 
sensitivity of GBM tumors to vosaroxin and vosaroxin 
plus RT is the recruitment of myeloid cells such as 
monocytes, macrophages, and microglia. This process 
plays a crucial role in neuroinflammation and has been 
recently identified as a novel therapeutic target, especially 
for chronic forms of neuroinflammation [47]. 
Macrophage functions are generally categorized as 
M1 or M2. M1 refers to the classically activated, polarized 
macrophages, while M2 refers to the alternatively 
activated macrophages. M1 macrophages differ from 
M2 in terms of receptor expression, cytokine production, 
effector functions, and chemokines. M1 macrophages are 
differentiated by microbial products such as LPS, by IFNγ-
produced TH1 cells during an adaptive immune response, 
or by natural killer cells during an innate immune 
response. M1 macrophages have tumor-killing capacity 
and express a number of factors including iNOS, IL-1β, 
and TNF-α. In contrast, M2 macrophages differentiate to 
several subtypes dependent on external stimulation [47]. 
The preliminary characterization of M1 and M2 
macrophages in this study suggested that vosaroxin 
induces an acute response from M1 macrophages, while 
RT is associated with M2 macrophage activity and may be 
associated with an elevated risk of recurrence. However, 
additional molecular characterization is necessary to obtain 
conclusive data and will be the subject of a separate report. 
The possible involvement of proliferating 
monocytes is also invoked due to the presence of close 
“germinal cores/cluster” dispersed in the necrotic tumor 
masses. This event could have dual effects: to participate 
in the elimination of necrotic cells (resolution) or to 
mediate the awakening of quiescent stem cells (leading to 
recurrence). The latter effect was not supported by results 
in the orthotopic models, which demonstrated no increase 
in recurrence with vosaroxin and the vosaroxin plus RT 
combination after only 35 days of treatment (1 treatment 
cycle). The rate of recurrence and the survival percentage 
in combination treatment were significantly better than 
those observed for the standard treatment, temozolomide 
plus RT, providing evidence against recurrence due to 
stimulation of cancer stem cells.
These data demonstrate that vosaroxin is a broadly 
active antitumor agent in vitro and in vivo, with potent 
activity in aggressive and temozolomide-resistant 
glioblastoma tumor models, supporting ongoing clinical 
evaluation of this compound both alone and in combination 
with RT for the treatment of postsurgery glioblastoma 
patients. A limitation of this study is that no direct 
comparison of the antitumor effects between vosaroxin 
and other topoisomerase inhibitors was performed. This 
topic may be of interest to others in future research.
MATERIALS AND METHODS
Reagent and drug preparation
All the materials for tissue culture were purchased 
from HyClone (Cramlington, UK). Plasticware was 
obtained from Nunc (Roskilde, Denmark). Antibodies for 
β-actin (sc-130065), p-DNA-PKCs (Thr 2609; sc-101664), 
Rad-51 (sc-8349), γ-H2AX (Ser 139; sc-101696), FAS 
(C-20; sc-715) and FAS-L (N-20; sc-834], CD68 (H-255; 
sc-9139), CD20 (M20; sc-7735), matrix metalloproteinase 
(MMP)-2 (4D3; sc-53630), and CXCR4 (4G10; sc-53534) 
were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Survivin antibody was purchased from 
Biorbyt (Cambridge, UK). Vosaroxin was kindly provided 
by Sunesis Pharmaceuticals, Inc. For in vitro cell viability 
assays, vosaroxin was dissolved in 0.17% methanesulfonic 
acid (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), 
forming a stock solution of 10 mM. Working solutions 
were made by dilution of the stock solution with cell 
culture media. The in vivo formulation of vosaroxin 
Table 5: Hazard ratios for disease-free survival and overall survival in orthotopic U251 models
Treatments Compared
Disease-free Survival Overall Survival
HR (95% CI) P Value HR (95% CI) P Value
TMZ vs VSR 2.0 (0.9–5.5) 0.06 (NS) 3.0 (1.0–8.8) 0.0446
RT vs VSR + RT 3.5 (1.2–9.9) 0.0007 9.9 (2.9–34.1) < 0.0001
VSR vs VSR + RT 2.4 (1.1–8.8) 0.0244 4.5 (2.2–22.5) 0.0001
VSR vs TMZ + RT 1.2 (0.4–3.2) 0.66 (NS) 1.5 (0.5–3.0) 0.78 (NS)
VSR + RT vs TMZ + RT 2.5 (1.0–6.2) 0.0088 3.7 (1.2–11.0) 0.0198
CI: confidence interval; HR: hazard ratio; NS: not significant; RT: radiotherapy; TMZ: temozolomide; VSR: vosaroxin.
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(10 mg/mL) was used for in vivo studies and further 
diluted for injection into mice by dilution with vehicle 
(0.17% methanesulfonic acid in 5% sorbitol; formulation 
reagents from Sigma-Aldrich). Temodal® (temozolomide) 
was purchased from Selleckchem labs (Aurogene, Rome, 
Italy). Anti-MIB1 (Ki67) was purchased from Dako (Dako 
Italia SPA, Milan, Italy). Pan-caspase inhibitor z-Val-Ala-
Asp(Ome)-fluoromethyl ketone and autophagy inhibitor 
3-methyladenine were purchased from Sigma-Aldrich. 
Cell lines
Thirteen human glioma cell lines (U251, U373, 
SNB19, U118, U138, U87MG, A172, LN229, LN19, 
SW1783, T98G, SF-268, and D54) were cultured at 37°C 
in 5% CO2 and were maintained in Dulbecco’s modified 
Eagle medium (DMEM) containing 10% (v/v) fetal 
bovine serum, 4 mM glutamine, 100 IU/mL penicillin, 
100 μg/mL streptomycin, and 1% nonessential amino 
acid (Invitrogen Life Technologies, Inc., Rockville, 
MD, USA). To minimize the risk of working with 
misidentified and/or contaminated cell lines, the cells 
used in studies reported here were stocked at very low 
passages after initial receipt from the vendor to reduce 
the possibility of contaminated cell line stocks and used 
at < 20 subcultures. Periodically, DNA profiling by 
GenePrint® 10 System (Promega Corporation, Madison, 
WI, USA) was carried out to authenticate cell cultures. 
Luciferase-transfected U251 cells were kindly provided 
by Jari E. Heikkila, department of Biochemistry and 
Pharmacy, Abo Akademi University, Turku, Finland. 
Three GBM patient-derived stem cell lines, BT12M, 
kindly provided by J. Gregory Cairncross and Samuel 
Weiss (Hotchkiss Brain Institute, Faculty of Medicine, 
University of Calgary, Calgary, Alberta, Canada) [56] and 
CSCs-5 and CSCs-7 from Marta Izquierdo (Departamento 
de Biología Molecular, Universidad Autónoma de Madrid, 
Spain) [57], were maintained as neurosphere cultures in 
Neurocult medium (Stem Cell Technologies, Vancouver, 
BC, Canada) supplemented with epidermal growth factor 
(20 ng/mL) and fibroblast growth factor (10 ng/mL). 
These non-commercially available, patient-derived cells 
were analyzed using short tandem repeat profiles. The 
expression of MGMT, p53, and PTEN was detected in 
western blots with antibodies from Santa Cruz against 
MGMT (sc166528), wt p53 (sc-100), total p53 (sc-126), 
and PTEN (sc-7974). 
Inhibition of proliferation assays
Cells were seeded at a density of 2 × 104 cells/mL 
in 24-well plates. Cells were left to attach and grow in 5% 
fetal bovine serum in DMEM for 24 hours. Cells were 
treated with different doses of radiation or temozolomide 
and then maintained in the appropriate culture conditions. 
At the conclusion of the treatment period, cells were 
trypsinized and resuspended in 1.0 mL of saline; viable 
cells were counted using the NucleoCounter™ NC-100 
(Chemotec, Cydevang, Denmark). All experiments were 
conducted in triplicate. IC50 values were calculated using 
GraFit (Erithacus Software Limited, Staines, UK).
Cell cycle and apoptosis analyses
Cell cycle analyses were performed using FxCycle™ 
Far Red (Life Technologies Europe BV, Monza, Italy). 
Apoptosis was analyzed with the Alexa Fluor® 488 Annexin 
V/Dead Cell Apoptosis Kit. Both analyses were measured 
on a Tali® image-based cytometer quantifying fluorescence 
emission at 530 nm (eg, FL1) and > 575 nm [58]. The 
results were expressed as the ratio of apoptosis in treated 
cells to apoptosis in vehicle-treated control cells.
Clonogenic survival assays
For clonogenic survival assays, exponentially 
growing cells (70% confluence) were cultured in regular 
media and treated with vosaroxin, at the appropriate 
concentrations, or vehicle (final dimethyl sulfoxide 
concentration of 0.1%) for 48 hours. Tumor cells were 
then irradiated at room temperature with increasing doses 
of radiation (0–6 Gy) using an x-ray linear accelerator 
(dose rate of 200 cGy/min). Nonirradiated controls 
were handled identically to the irradiated cells with the 
exception of the radiation exposure. After treatment, cells 
were diluted at the appropriate concentration (1000 cells 
in 10 mL) and reseeded into a new 100 mm tissue culture 
dish (in triplicate) and incubated for 14 days. At day 14, 
the medium was removed and colonies were fixed with 
methanol:acetic acid (10:1, v/v), and stained with crystal 
violet. Colonies containing more than 50 cells were 
counted. The plating efficiency was calculated as the 
number of colonies observed divided by the number of 
cells plated. The surviving fraction was calculated as the 
number of colonies formed in the treated dishes compared 
with the number formed in the control. The survival 
curves were analyzed using SPSS statistical software 
(Chicago, IL, USA) by means of a fit of the data by a 
weighted, stratified, linear regression, according to the 
linear-quadratic formula: S(D)/S(O) = exp-(αD + βD2). The 
cell survival enhancement ratio was calculated as the ratio 
of the mean inactivation dose under control conditions 
divided by the mean inactivation dose after treatment as 
previously described [59, 60].
Detection and quantification of autophagic cells 
by staining with acridine orange
As a marker of autophagy we evaluated the presence 
of AVOs after staining of cell cultures with LysoTracker® 
Red DND-99 kit (Life Technologies Italia, Monza, 
Italy) according to the manufacturer’s instructions. The 
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intensity of the red fluorescence is proportional to the 
degree of acidity. The percentage of autophagic cells was 
quantified with the Tali® Image-Based Cytometer (Life 
Technologies) measuring fluorescence emission at 590 
nm with fluorescence excitation at 577 nm. The results 
were expressed as the percentage of cell AVOs stained in 
controls and in treated cultures.
Preparation of cell lysates and Western blot 
analysis
Cells grown in 90 mm diameter Petri dishes were 
treated and at various timepoints were washed with cold 
phosphate-buffered saline (PBS) and immediately lysed 
with 1 mL radioimmunoprecipitation assay (RIPA) buffer 
containing protease and phosphatase inhibitor cocktail. 
Total lysates were electrophoresed in SDS-PAGE (7%), 
and separated proteins transferred to nitrocellulose 
and probed with the appropriate antibodies using the 
conditions recommended by the suppliers. Protein levels 
in total extracts were normalized to actin.
ELISA determinations
After appropriate treatments, tumor cell cultures and 
tissues were harvested for analysis of cytokine expression. 
Cell pellets were washed with PBS and lysed with RIPA 
buffer. Cell lysates and conditioned media were assayed by 
ELISA to measure (i) active human caspase-3 (CBA045, 
Merck Chemicals Ltd., Nottingham, UK), (ii) beclin-1 
(E98557Hu, USCN Life Sciences, Houston, TX, USA), 
and (iii) DNA damage (EpiQuik in situ DNA Damage 
Assay Kit, Epigentek, Farmingdale, NY, USA). Tumor 
extracts were analyzed for the presence of:
(i) MMP-2 (KHC3081)
(ii)  TNF-α (KHC3011, Life Technologies Italia, 
Monza, Italy)
(iii)  CXCR4 (Cyto Glow CXCR4 [pSer339], cell-based 
ELISA, Assay Biotech, Sunnyvale, CA, USA)
(iv)  Human Fas ligand (ELH-FASL, RayBiotech, 
Norcross, GA, USA)
(v)  IL-6 (orb50052) and survivin (orb50135) (Biorbyt)
(vi)  TGF-β1 (Quantikine ELISA Kit, DB100B, R&D 
Systems, Minneapolis, MN, USA) 
(vii)  SDF-1α (Human CXCL12/SDF-1α Quantikine 
ELISA Kit, DSA00, R&D Systems) 
(viii)  Mouse IL-10 DuoSet ELISA DY417 (R&D 
Systems Minneapolis, MN, USA)
(ix)  Mouse NOS2 / iNOS ELISA Kit (Sandwich 
ELISA) - LS-F12166 (LifeSpan Biosciences, Inc, 
Seattle, WA, USA)
(x)  Mouse ARG1 / Arginase-1 ELISA Kit (Sandwich 
ELISA) - LS-F10883 (LifeSpan Biosciences, Inc, 
Seattle, WA, USA)
All determinations were performed in triplicate, 
according to manufacturers’ instructions. Data are 
presented as mean ± SE. Cytokine secretion determined 
by ELISA was normalized to total protein concentration 
in tissue lysates.
Mouse glioblastoma xenograft model
Female CD1-nu/nu mice, at 6 weeks of age, were 
purchased from Charles River (Milan, Italy) under the 
guidelines established by our institution (University of 
L’Aquila, Medical School and Science and Technology 
School Board Regulations, complying with Italian 
government regulation n.116, January 27, 1992, for the 
use of laboratory animals). All mice received subcutaneous 
flank injections (2 each) of 1 × 106 U251, U87MG, and 
T98G cells representing models for MGMT-negative 
and MGMT-positive cells. Tumor growth was assessed 
biweekly by measuring tumor diameters with a Vernier 
caliper (length × width). Tumor weight was calculated 
according to the formula tumor weight (mg) = tumor 
volume (mm3) = d2 × D/2, where d and D are the shortest 
and longest diameters, respectively. The effects of the 
treatments were assessed as previously described [36]. 
At about 10 days after the tumor injection, 30 mice with 
tumor volumes of 0.5–0.8 cm3 were randomly divided 
into 6 groups (5 mice per group with 2 tumors each): (1) 
control (vehicle); (2) vosaroxin (10 mg/kg every 5 days 
for 5 weeks intravenous [IV] injection into tail vein; (3) 
radiotherapy (RT; 4 Gy delivered in a single fraction) [59]; 
(4) vosaroxin in combination with RT; (5) temozolomide 
(16 mg/kg 5 consecutive days) and (6) temozolomide in 
combination with RT. Anesthetized tumor-bearing mice 
received focal irradiation. Irradiation was delivered using 
an x-ray linear accelerator at a dose rate of 200 cGy/min at 
room temperature. All mice were shielded with a specially 
designed lead apparatus to allow irradiation to the right 
hind limb. At the end of the study (35 days after the start 
of treatments), animals were sacrificed by carbon dioxide 
inhalation and tumors were then removed surgically. Half of 
the tumor was directly frozen in liquid nitrogen for protein 
analysis and the other half was fixed in paraformaldehyde 
overnight for immunohistochemical analyses. 
Immunohistochemical evaluations
Indirect immunoperoxidase staining of tumor 
xenograft samples was performed on paraffin-embedded 
tissue sections (4 μm); sections were incubated with 
primary antibodies overnight at 4°C. Avidin-biotin 
assays were performed using the Vectastain Elite kit 
(Vector Laboratories, Burlingame, CA, USA). Mayer’s 
hematoxylin was used as nuclear counterstain. Tumor 
microvessels were counted at 400× magnification in 
5 arbitrarily selected fields and the data were presented as 
number of CD31-positive microvessels/100× microscopic 
field for each group. Ki67 labeling index was determined 
by counting 500 cells at 100× and determining the 
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percentage of cells staining positively for Ki67. Apoptosis 
was measured as the percentage of tunnel positive cells ± 
standard deviation (SD) measured on 5 random fields 
(400×). The presence of hematopoietic cells in tumor 
tissue and in blood vessels as well as the presence of 
microthrombi and bleeding zones was demonstrated by 
Martius yellow-brilliant crystal scarlet blue technique. 
Tumor hemoglobin levels were also quantified as 
previously described [61].
Evaluation of treatment response in vivo 
(xenograft model)
The following parameters were used to quantify 
the antitumor effects of different treatments as previously 
described [59]: tumor volume, measured throughout the 
experiment; tumor weight, measured at the end of the 
experiment; tumor progression, defined as an increase 
of greater than 50% of tumor volume with respect to 
baseline; and time to progression (TTP), defined as the 
time until tumor progression was observed from baseline. 
Tumor size was measured with calipers and the TTP of 
a single tumor was calculated. TTP data were used to 
generate Kaplan-Meier curves for progression. This 
method of analysis was described previously [59, 62], and 
may reduce both inter-subject variability resulting from 
differences in engraftment efficacy as well as intra-subject 
variability in response. 
In vivo drug combination studies were 
evaluated using CalcuSyn. For CI calculations of dual 
administration, the values of % cell kill (%CK) for a fixed 
tumor volume were determined by the log CK (LCK). 
LCK was calculated as LCK = (T − C) / (3.32 × Td), 
where Td represented the mean control group doubling 
time required to reach a fixed tumor volume, expressed 
in days. T and C were the mean times in days required to 
reach the same fixed tumor volume in the treated group 
and the control group, respectively. CK was calculated as 
%CK = [1 − (1 − 10LCK)] × 100. Tumor growth delay 
(TGD) was calculated as %TGD = [(T − C) / C] × 100, 
where T and C were the same values as those reported by 
Bruzzese et al. [63].
Distribution of [14C]-vosaroxin to brain
A single IV dose of [14C]-vosaroxin (1.84 MBq/kg 
with 20 mg/kg unlabeled vosaroxin) was administered 
to nude mice bearing human nasopharyngeal tumors. 
Radiochemical purity was > 96%. For determination of 
plasma and brain concentrations, 3 mice/time point were 
sacrificed at 5 minutes, 30 minutes, and 1, 3, 8, 24, and 
96 hours postdose. Blood samples were collected for 
plasma, and the cerebrum and cerebellum were harvested 
following exsanguination. Radioactivity in plasma 
was counted directly after addition of tissue-dissolving 
solution and scintillation liquid. Radioactivity in brain was 
determined after combustion. Radioactivity concentrations 
were converted into vosaroxin concentrations and 
expressed as mean ± standard error of the mean. When 
the statistical error of the counted sample radioactivity 
exceeded 5% of the counts, the sample radioactivity was 
defined to be under the reliable limit of measurement.
Orthotopic intra-brain model
Orthotopic luciferase-transfected U251 tumor 
growth and therapy studies were conducted with an 
approved animal-use protocol. Nude mice were inoculated 
intracerebrally [64] as follows: animals were anesthetized 
with 100 mg/kg ketamine, 15 mg/kg xylazine, and 
0.05 mL atropine intramuscularly; the surgical zone was 
swabbed with Betadine solution and the eyes coated with 
Lacri-lube; the head was fixed in a stereotactic frame 
(mouse stereotaxics instrument, Stoelting Europe, Dublin, 
Ireland) and a midline scalp incision was made; a small 
hole was made at 1.0 mm anterior and 2 mm lateral to 
the exposed bregma; a sterile 5 µL Hamilton syringe 
with a 26-gauge needle was inserted at a depth of 3.0 mm 
from the skull surface and withdrawn by 0.5 mm to inject 
3 × 103 U87MG cells in a volume of 3 µL at an injection 
up to 1 µL/min. After the implantation of the tumor cells, 
the needle was left in place for 5 minutes to prevent reflux. 
The needle was then completely withdrawn from the 
brain over the course of 4 minutes (1.0 mm/min) and the 
skin was sutured. Just before treatment initiation (5 days 
after injection), animals were randomized to treatment 
groups of 10 mice each. In vivo bioluminescence images 
were obtained using a Hamamatsu camera (Hamamatsu 
Photonics Italy S.R.L, Arese, Italy) to identify intracranial 
implants similar to the method described by Kemper 
et al. [65]. Animals were anesthetized and luciferin (150 
mg/kg) was injected intraperitoneally 15 minutes prior to 
imaging. The mice were photographed while placed on 
their front and the bioluminescence intensity (BLI) was 
measured in the region of interest. The BLI value just 
prior to the initiation of the treatment was used to calculate 
the %BLI of increment for each individual animal. We 
deliberately inoculated a small number of cells (3 × 103) 
to simulate a chemo-radiotherapeutic treatment made after 
surgery in which a low number of tumor cells, remaining 
in the operatory bed, regrows and gives rise to a recurrence 
as described previously [62]. Treatments were started 5 
days after cell injection when no luciferase activity was 
intracranially detectable. Tumor growth delay (recurrence 
time equivalent of DFS) was evaluated by assessment 
of intracranial luciferase activity by BLI, and also by 
magnetic resonance imaging (MRI) [66]. BLI photon 
counts and tumor volumes from MRI were correlated. 
Mice were euthanized when they displayed neurological 
signs (eg, altered gait, tremors/seizures, lethargy) or 
weight loss of 20% or greater of presurgical weight and 
OS was recorded. 
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Magnetic resonance imaging
All MRI studies were performed using a MR750w 
3.0T scanner (GE Healthcare, Little Chalfont, UK) with 
a 16-channel phased array flex wrist coil. Mice were 
placed prone in a plastic holder for ease of fixation and 
anesthetized to avoid movement during imaging. All 
images were obtained in the transverse plane using the 
following sequences: transverse T2-weighted turbo spin-
echo sequence (repetition time msec/echo time msec) 
6766/120, echo train length of 25, one signal acquired, 
matrix of 192 × 192) applied with a section thickness of 
0.9 mm, an intersection gap of 0.0 mm, and a flip angle of 
160°. The field of view was 36 × 60 mm2, which included 
the tumor in its entirety (20 sections) with a resultant 
voxel size of 0.3 × 0.3 × 1.0 mm3.
Statistics
Continuous variables were summarized as mean 
and SD or as median and 95% confidence interval. For 
continuous variables not normally distributed, statistical 
comparisons between control and treated groups were 
established by Kruskal-Wallis test. When the Kruskal-
Wallis test revealed a statistical difference, pairwise 
comparisons were made by the Dwass-Steel-Critchlow-
Fligner method and the probability of each presumed 
“non-difference” was indicated. For continuous variables 
normally distributed, statistical comparisons between 
control and treated groups were established by analysis of 
variance (ANOVA) test or by Student t-test for unpaired 
data (for 2 comparisons). When the ANOVA test revealed 
a statistical difference, pairwise comparisons were made 
by Tukey’s honestly significant difference test and the 
probability of each presumed “non-difference” was 
indicated. Dichotomous variables were summarized by 
absolute and/or relative frequencies. For dichotomous 
variables, statistical comparisons between control and 
treated groups were established by the Fisher’s exact 
test. For multiple comparisons, the level of significance 
was corrected by multiplying the P value by the number 
of comparisons performed (n) according to Bonferroni 
correction. TTP was analyzed by Kaplan-Meier curves 
and Gehan’s generalized Wilcoxon test. When more than 
2 survival curves were compared, the log-rank test for 
trend was used to test the probability of a trend in survival 
scores across the groups. All tests were 2-sided and were 
determined by Monte Carlo significance. P values < 0.05 
were considered statistically significant. SPSS statistical 
analysis software package version 10.0 and StatDirect 
version 2.3.3 (StatsDirect Ltd, Altrincham, UK) were used 
for statistical analysis and graphic presentation.
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